Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | CDK4 | P11802 | 1/20 | 0.55 |
| ▸ | CCND1 | P24385 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198903 | 0.88 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL7951597 | 0.84 | ALDH1A1 (0.77) | ALDH1A1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL11183187 | 0.81 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL7589564 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL3115249 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL19908414 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL3233063 | 0.81 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL3108676 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL16372262 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL30487785 | 0.81 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2ACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2620429-A1 | Hydroxylamine compounds and methods of their use | Colby Pharmaceutical Company (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-1802297-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | BURNHAM INST (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20090312352-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-17 | — | — | US | disclosed |
| EP-2120942-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | Othera Holding, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1802297-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | The Burnham Institute (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007058960-A1 | SULFAMOYL BENZAMIDES AS CANNABINOID RECEPTOR MODULATORS | ADOLOR CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| WO-2006047162-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | THE BURNHAM INSTITUTE (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-13 | — | — | US | disclosed |
| US-3983121-A | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 1976-09-28 | — | — | US | disclosed |
| US-3983121-A | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 1976-09-28 | — | — | US | disclosed |
| US-3983121-A | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | ALDH1A1 750/4885MEN1 4753/4885KMT2A 1865/4885 |
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | CNR2, TRPV1, CNR1 | ALDH1A1 3146/4885MEN1 3148/4885KMT2A 1089/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | ALDH1A1 351/4885MEN1 4852/4885KMT2A 2063/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | ALDH1A1 750/4885MEN1 4753/4885KMT2A 1865/4885 |
| US-20090312352-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | PTPRS, PTPRO, PTPN5 | ALDH1A1 4492/4885MEN1 2038/4885KMT2A 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.